检索结果-南通市图书馆

一项免疫组织化学研究证实卵巢颗粒细胞瘤经常会表达表皮生长因子受体(Her-1)、Her-3和Her-4

世界核心医学期刊文摘（妇产科学分册） 2006年第6期2卷 56-57页

作者： leibl s. Bodo K. Gogg- Kammerer M. F.Moinfar 丁福 Department of Pathology Medical University of Graz Auenbruggerplatz 25 A- 8036 Graz Austria

Objective. Up to 50% of patients.with ovarian granulos. cell tumors.(GCTs. will develop recurrences. s.me of thes. recurrences.can be s.en as.late as.30 years.following the initial s.rgical treatment. Combined chemotherapy and radiotherapy are currently us.d for patients.with advanced or recurrent dis.as.. The aim of this.s.udy was.to inves.igate the pos.ible eligibility of patients.with GCTs.for anti- Her therapy. Methods. The immunohis.ochemical expres.ion of EGFR (Her- 1), Her- 2, Her- 3, and Her- 4 was.analyzed in a group of ovarian GCTs.encompas.ing 38 adult type and 2 juvenile type. Res.lts. Thirty- one cas.s.(77.5% ) were pos.tive for at leas. one of the receptors.EGFR (Her- 1), Her- 3, and Her- 4. Twenty- s.x out of 40 (65% ) GCTs.s.owed pos.tive reaction for EGFR (Her- 1). Eight tumors.(20% ) were exclus.vely pos.tive for EGFR (Her- 1). None of 40 cas.s.s.owed a pos.tive reaction for Her- 2. Pos.tive reactions.for Her- 3 and Her- 4 were obs.rved in 18 (45% ) and 23 (57.5% ) tumors. Only one cas. (2.5% ) was.exclus.vely pos.tive for Her- 4. Four tumors.(10% ) s.owed pos.tivity for Her- 3 and Her- 4 but were negative for EGFR (HER- 1). While one of the two JGCTs.was.negative for all members.of the Her- family, one s.owed reactivity for EGFR (Her- 1), Her- 3, and Her- 4. Conclus.on. In this.s.udy, mos. of the ovarian GCTs.expres. at leas. one of the receptors.EGFR (Her- 1), Her- 3, and Her- 4. Thes. findings.provide s.me evidence to further explore the potential us. of agents.targeting thes. receptors.(particularly EGFR) in the treatment of ovarian GCTs.

关键词：卵巢颗粒细胞瘤表皮生长因子受体免疫组织化学研究 Her-2阳性免疫组化法联合治疗表达情况

来源：